NOV 13, 2019 9:27 AM PST

The Side-Effects to A Common Blood Cancer Drug

WRITTEN BY: Nouran Amin

In a study published in Scientific Reports, a popular cancer drug, known as ruxolitnib, was found to cause an increased weight gain as well as an increase in liver enzymes and systolic blood pressure.

“Weight gain with ruxolitinib has previously been reported in clinical trials, but our study provides real-world experience regarding the extent of that weight gain,” said Emily J. Gallagher, MD, PhD, the study’s lead author and Assistant Professor of Medicine (Endocrinology, Diabetes and Bone Disease) at the Icahn School of Medicine at Mount Sinai, specializing in onco-endocrinology, the treatment of endocrine complications of oncology treatments. “We recommend that patients who go on this medication and do have an increase in weight get a full metabolic evaluation.”

Researchers from Icahn School of Medicine at Mount Sinai reported in their study that the FDA-approved ruxolitinib, which was the first and most widely prescribed in treating blood cancers, holds strong metabolic effects. Ruxolitinib treats the particular blood cancer group known as myeloproliferative neoplasms (MPNs), which includes myelofibrosis and polycythemia vera. The drug blocks the enzyme Janus kinases (JAK) ½ resulting in the inhibition of blood cell production. Although previous studies have noted the side-effects, researchers are now beginning to understand the long-term consequences of cancer therapeutics on metabolic health.

Learn more about the mechanism of action:

“In contrast to the perception of many health care providers, patients are not going from being underweight to being a normal weight. Instead, a significant number of patients are developing obesity. Based on these results, physicians should be aware of the potential effects, and counsel patients accordingly,” said Dr. Gallagher.

Source: Mount Sinai Health

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 20, 2020
Cancer
JAN 20, 2020
Did you know these non-cancer drugs can also fight cancer?
A study from MIT. Harvard and the Dana-Farber Cancer Institute has concluded that almost 50 existing non-oncological drugs have anti-cancer properties capa...
FEB 12, 2020
Drug Discovery & Development
FEB 12, 2020
Does Traditional Chinese Medicine Work Against Coronavirus?
Over 45,000 cases of Wuhan Coronavirus have been reported globally, alongside over 1,100 deaths. Although over 4,700 people are said to have recovered from...
FEB 26, 2020
Microbiology
FEB 26, 2020
NIAID Tests Remdesivir as a Treatment for COVID-19
A case of coronavirus has now occured in the US in someone without a known link to an infected person or travel....
MAR 18, 2020
Genetics & Genomics
MAR 18, 2020
Finding a Treatment for Fetal Alcohol Spectrum Disorder
When developing fetuses are exposed to any amount of alcohol, they are at risk for a variety of irreversible birth defects....
MAR 23, 2020
Cancer
MAR 23, 2020
An Alternative Use for Common Kidney Cancer Drug to Fight Against Epithelial Ovarian Cancer
Axitinib is a small molecule drug that inhibits VEGFR tyrosine kinases 1, 2, and 3. Shown previously to potentially prevent angiogenesis and promote apoptosis in cancer cells...
MAR 18, 2020
Drug Discovery & Development
MAR 18, 2020
Drug Treatments Used For Cattle Affect Wildlife
Common drug treatments used in cattle, such as de-worming and anti-ectoparasitic products, have held effect on wildlife which urged researchers to find imm...
Loading Comments...